Literature DB >> 24492522

Association between the lipoprotein-associated phospholipase A2 activity and the progression of subclinical atherosclerosis.

Jing Liu1, Wei Wang, Yue Qi, Qiang Yong, Guanghua Zhou, Miao Wang, Jiayi Sun, Jun Liu, Zhangrong Jia, Dong Zhao.   

Abstract

AIM: The lipoprotein-associated phospholipase A2(Lp-PLA2) level has been shown to be associated with the risk of clinical cardiovascular events. We aimed to investigate whether Lp-PLA2 is associated with the progression of subclinical atherosclerosis in the general population.
METHODS: The degree of carotid plaque and the maximal intima-media thickness(IMT) were measured twice over a 5-year interval in 913 participants 45 to 74 years of age at baseline in a cohort study. The associations between the plasma Lp-PLA2 activity and the progression of carotid plaque and changes in the IMT level were assessed according to sex after adjusting for traditional risk factors and the high-sensitivity C-reactive protein(hsCRP) level.
RESULTS: During the 5-year follow-up period, the progression of plaque was observed in 58.5% of men and 48.3% of women. The median maximal IMT level increased by 0.12 mm in men and 0.09 mm in women per year. The progression of plaque and changes in the IMT level increased according to the quartile of the Lp-PLA2 activity in men(p<0.05 for trend), but not women. Following adjustment for traditional risk factors and the hsCRP level, the odds ratio for plaque progression associated with an increase in the Lp-PLA2 activity of one standard deviation was 1.28(95% CI=1.09-1.49, p=0.043) in men and 0.92(95% CI=0.78-1.08, p=0.273) in women. The regression coefficient for IMT progression was 0.003(p=0.004) in men and -0.001(p=0.166) in women after adjusting for the other factors.
CONCLUSIONS: The Lp-PLA2 level is associated with the progression of subclinical atherosclerosis in men. Lp-PLA2 may play an important role in the pathogenesis of atherosclerosis and be a potential target for the early prevention of cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24492522

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN: 1340-3478            Impact factor:   4.928


  13 in total

1.  Nonsynonymous polymorphisms in PLA2G7 gene are associated with the risk of coronary heart disease in a southern Chinese population.

Authors:  Mei Hong; Mengyao Zhang; Xiang Lu
Journal:  Mamm Genome       Date:  2015-02-18       Impact factor: 2.957

2.  Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease.

Authors:  Lars Wallentin; Claes Held; Paul W Armstrong; Christopher P Cannon; Richard Y Davies; Christopher B Granger; Emil Hagström; Robert A Harrington; Judith S Hochman; Wolfgang Koenig; Sue Krug-Gourley; Emile R Mohler; Agneta Siegbahn; Elizabeth Tarka; Philippe Gabriel Steg; Ralph A H Stewart; Robert Weiss; Ollie Östlund; Harvey D White
Journal:  J Am Heart Assoc       Date:  2016-06-21       Impact factor: 5.501

3.  A previously unreported impact of a PLA2G7 gene polymorphism on the plasma levels of lipoprotein-associated phospholipase A2 activity and mass.

Authors:  Yue Qi; Dong Zhao; Zhangrong Jia; Wei Wang; Miao Wang; Jiayi Sun; Jun Liu; Yan Li; Wuxiang Xie; Jing Liu
Journal:  Sci Rep       Date:  2016-12-01       Impact factor: 4.379

4.  Low Very low-Density Lipoprotein Cholesterol but High Very low-Density Lipoprotein Receptor mRNA Expression in Peripheral White Blood Cells: An Atherogenic Phenotype for Atherosclerosis in a Community-Based Population.

Authors:  Fan Zhao; Yue Qi; Jing Liu; Wei Wang; Wuxiang Xie; Jiayi Sun; Jun Liu; Yongchen Hao; Miao Wang; Yan Li; Dong Zhao
Journal:  EBioMedicine       Date:  2017-08-31       Impact factor: 8.143

5.  Association of lipoprotein-associated phospholipase A2 mass with asymptomatic cerebral artery stenosis.

Authors:  Youxin Wang; Bin Zhou; Pingan Zhou; Yan Yao; Qinghua Cui; Yingping Liu; Jichun Yang; Shouling Wu; Xingquan Zhao; Yong Zhou
Journal:  J Cell Mol Med       Date:  2018-02-09       Impact factor: 5.310

6.  Association of lipoprotein-associated phospholipase A2 and risk of incident atrial fibrillation: Findings from 3 cohorts.

Authors:  Parveen K Garg; Traci M Bartz; Faye L Norby; Neal W Jorgensen; Robyn L McClelland; Christie M Ballantyne; Lin Y Chen; John S Gottdiener; Philip Greenland; Ron Hoogeveen; Nancy S Jenny; Jorge R Kizer; Robert S Rosenson; Elsayed Z Soliman; Mary Cushman; Alvaro Alonso; Susan R Heckbert
Journal:  Am Heart J       Date:  2017-12-05       Impact factor: 4.749

7.  Is Lipoprotein-Associated Phospholipase A2 a Link between Inflammation and Subclinical Atherosclerosis in Rheumatoid Arthritis?

Authors:  Anna Södergren; Kjell Karp; Christine Bengtsson; Bozena Möller; Solbritt Rantapää-Dahlqvist; Solveig Wållberg-Jonsson
Journal:  Biomed Res Int       Date:  2015-10-04       Impact factor: 3.411

8.  Lipids and lipoproteins and inflammatory markers in patients with chronic apical periodontitis.

Authors:  Aleksandra Kimak; Małgorzata Strycharz-Dudziak; Teresa Bachanek; Elżbieta Kimak
Journal:  Lipids Health Dis       Date:  2015-12-14       Impact factor: 3.876

9.  A Nested Case-Control Study of Association between Metabolome and Hypertension Risk.

Authors:  Yongchen Hao; Ying Wang; Lu Xi; Guoqi Li; Fan Zhao; Yue Qi; Jing Liu; Dong Zhao
Journal:  Biomed Res Int       Date:  2016-03-29       Impact factor: 3.411

10.  Lp-PLA2, scavenger receptor class B type I gene (SCARB1) rs10846744 variant, and cardiovascular disease.

Authors:  Ani Manichaikul; Xin-Qun Wang; Li Li; Jeanette Erdmann; Guillaume Lettre; Joshua C Bis; Dawn Waterworth; Mary Cushman; Nancy S Jenny; Wendy S Post; Walter Palmas; Michael Y Tsai; Lars Wallentin; Harvey White; Heribert Schunkert; Christopher J O'Donnell; David M Herrington; Stephen S Rich; Michelle L O'Donoghue; Annabelle Rodriguez
Journal:  PLoS One       Date:  2018-10-05       Impact factor: 3.752

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.